• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Angew Chem Int Ed Engl . Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Ag

tetano

Editor, Senior Moderator
Angew Chem Int Ed Engl


. 2021 Jan 19.
doi: 10.1002/anie.202015362. Online ahead of print.
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine


Sonia Jangra[SUP] 1 [/SUP], Jana De Vrieze[SUP] 2 [/SUP], Angela Choi[SUP] 1 [/SUP], Raveen Rathnasinghe[SUP] 1 [/SUP], Gabriel Laghlali[SUP] 1 [/SUP], Annemiek Uvyn[SUP] 3 [/SUP], Simon Van Herck[SUP] 4 [/SUP], Lutz Nuhn[SUP] 5 [/SUP], Kim Deswarte[SUP] 6 [/SUP], Zifu Zhong[SUP] 2 [/SUP], Niek Sanders[SUP] 7 [/SUP], Stefan Lienenklaus[SUP] 8 [/SUP], Sunil David[SUP] 9 [/SUP], Shirin Strohmeier[SUP] 1 [/SUP], Fatima Amanat[SUP] 1 [/SUP], Florian Krammer[SUP] 1 [/SUP], Hamida Hammad[SUP] 6 [/SUP], Bart N Lambrecht[SUP] 6 [/SUP], Lynda Coughlan[SUP] 1 [/SUP], Adolfo Garc?a-Sastre[SUP] 1 [/SUP], Bruno de Geest[SUP] 10 [/SUP], Michael Schotsaert[SUP] 1 [/SUP]



Affiliations

Abstract

The search for vaccines that protect from severe morbidity and mortality as a result of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19) is a race against the clock and the virus. Here we describe the use of a novel amphiphilic imidazoquinoline (IMDQ-PEG-CHOL) TLR7/8 adjuvant, consisting of an imidazoquinoline conjugated to the chain end of a cholesterol-poly(ethylene glycol) macromolecular amphiphile. This amphiphile is water soluble and exhibits massive translocation to lymph nodes upon local administration, likely through binding to albumin, affording localized innate immune activation and a dramatic reduction in systemic inflammation. The adjuvanticity of IMDQ-PEG-CHOL was validated in the context of a licensed vaccine setting (i.e. the quadrivalent influenza vaccine) and an experimental trimeric recombinant SARS-CoV-2 spike protein vaccine, showing robust IgG2a and IgG1 antibody titers in mice that could neutralize viral infection in vitro and in vivo in a mouse model.

Keywords: vaccines, amphiphiles, innate immunity, SARS-CoV-2, COVID-19.
 
Back
Top Bottom